Reciprocal influences of CB1 cannabinoid receptor agonists on ERK and JNK signalling in N1E-115 cells

FEBS Letters

Volumn 582, Issue 28, 2008, Pages 3861-3867

  Bosier, Barbara ^a   Lambert, Didier M ^a   Hermans, Emmanuel ^a  

^a UNIVERSITÉ CATHOLIQUE DE LOUVAIN   (Belgium)

Author keywords

Cannabinoid receptor; Drug efficacy; Functional selectivity; G Protein coupled receptor; MAPK; Tyrosine hydroxylase

Indexed keywords

4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; CANNABINOID 1 RECEPTOR AGONIST; DEXANABINOL; G PROTEIN COUPLED RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; MITOGEN ACTIVATED PROTEIN KINASE KINASE 4; TYROSINE 3 MONOOXYGENASE; 3 (2 HYDROXY 4 (1,1 DIMETHYLHEPTYL)PHENYL) 4 (3 HYDROXYPROPYL)CYCLOHEXANOL; 3-(2-HYDROXY-4-(1,1-DIMETHYLHEPTYL)PHENYL)-4-(3-HYDROXYPROPYL)CYCLOHEXANOL; CANNABINOID 1 RECEPTOR; CYCLOHEXANOL DERIVATIVE; DRUG DERIVATIVE; MITOGEN ACTIVATED PROTEIN KINASE P38; TETRAHYDROCANNABINOL; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE EXPRESSION REGULATION; MOLECULAR INTERACTION; NEUROBLASTOMA CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; SIGNAL TRANSDUCTION; ANIMAL; DRUG POTENTIATION; METABOLISM; MOUSE; PHOSPHORYLATION; TUMOR CELL LINE;

ANIMALS; CELL LINE, TUMOR; CYCLOHEXANOLS; MAP KINASE KINASE 4; MICE; MITOGEN-ACTIVATED PROTEIN KINASE 1; MITOGEN-ACTIVATED PROTEIN KINASE 3; P38 MITOGEN-ACTIVATED PROTEIN KINASES; PHOSPHORYLATION; RECEPTOR, CANNABINOID, CB1; SIGNAL TRANSDUCTION; TETRAHYDROCANNABINOL;

EID: 55749113512     PISSN: 00145793     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.febslet.2008.10.022     Document Type: Article

References (44)

1. Mukhopadhyay S., and Howlett A.C. Chemically distinct ligands promote differential CB1 cannabinoid receptor-Gi protein interactions. Mol. Pharmacol. 67 (2005) 2016-2024
2. Bouaboula M., Poinot-Chazel C., Bourrie B., Canat X., Calandra B., Rinaldi-Carmona M., Le Fur G., and Casellas P. Activation of mitogen-activated protein kinases by stimulation of the central cannabinoid receptor CB1. Biochem. J. 312 Pt2 (1995) 637-641
3. Rueda D., Galve-Roperh I., Haro A., and Guzman M. The CB(1) cannabinoid receptor is coupled to the activation of c-Jun N-terminal kinase. Mol. Pharmacol. 58 (2000) 814-820
4. Rhee M.H., Bayewitch M., Avidor-Reiss T., Levy R., and Vogel Z. Cannabinoid receptor activation differentially regulates the various adenylyl cyclase isozymes. J. Neurochem. 71 (1998) 1525-1534
5. Glass M., and Felder C.C. Concurrent stimulation of cannabinoid CB1 and dopamine D2 receptors augments cAMP accumulation in striatal neurons: evidence for a Gs linkage to the CB1 receptor. J. Neurosci. 17 (1997) 5327-5333
6. Lauckner J.E., Hille B., and Mackie K. The cannabinoid agonist WIN55, 212-2 increases intracellular calcium via CB1 receptor coupling to Gq/11 G proteins. Proc. Natl. Acad. Sci. USA 102 (2005) 19144-19149
7. Bonhaus D.W., Chang L.K., Kwan J., and Martin G.R. Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses. J. Pharmacol. Exp. Ther. 287 (1998) 884-888
8. Bash R., Rubovitch V., Gafni M., and Sarne Y. The stimulatory effect of cannabinoids on calcium uptake is mediated by Gs GTP-binding proteins and cAMP formation. Neurosignals 12 (2003) 39-44
9. Rueda D., Navarro B., Martinez-Serrano A., Guzman M., and Galve-Roperh I. The endocannabinoid anandamide inhibits neuronal progenitor cell differentiation through attenuation of the Rapl/B-Raf/ERK pathway. J. Biol. Chem. 277 (2002) 46645-46650
10. Bosier B., and Hermans E. Versatility of GPCR recognition by drugs: from biological implications to therapeutic relevance. Trends Pharmacol. Sci. 28 (2007) 438-446
11. Sugiura T., Kodaka T., Nakane S., Miyashita T., Kondo S., Suhara Y., Takayama H., Waku K., Seki C., Baba N., and Ishima Y. Evidence that the cannabinoid CB1 receptor is a 2-arachidonoylglycerol receptor. Structure-activity relationship of 2-arachidonoylglycerol, ether-linked analogues, and related compounds. J. Biol. Chem. 274 (1999) 2794-2801
12. Shen M., Piser T.M., Seybold V.S., and Thayer S.A. Cannabinoid receptor agonists inhibit glutamatergic synaptic transmission in rat hippocampal cultures. J. Neurosci. 16 (1996) 4322-4334
13. Bosier B., Hermans E., and Lambert D.M. Differential modulation of AP-1- and CRE-driven transcription by cannabinoid agonists emphasizes functional selectivity at the CB1 receptor. Br. J. Pharmacol. 155 (2008) 24-33
14. Najimi M., Robert J.J., Mallet J., Rostene W., and Forgez P. Neurotensin induces tyrosine hydroxylase gene activation through nitric oxide and protein kinase C signaling pathways. Mol. Pharmacol. 62 (2002) 647-653
15. Pierreux C.E., Urso B., De Meyts P., Rousseau G.G., and Lemaigre F.P. Inhibition by insulin of glucocorticoid-induced gene transcription: involvement of the ligand-binding domain of the glucocorticoid receptor and independence from the phosphatidylinositol 3-kinase and mitogen-activated protein kinase pathways. Mol. Endocrinol. 12 (1998) 1343-1354
16. Bosier B., Tilleux S., Najimi M., Lambert D.M., and Hermans E. Agonist selective modulation of tyrosine hydroxylase expression by cannabinoid ligands in a murine neuroblastoma cell line. J. Neurochem. 102 (2007) 1996-2007
17. Toullec D., Pianetti P., Coste H., Bellevergue P., Grand-Perret T., Ajakane M., Baudet V., Boissin P., Boursier E., and Loriolle F. The bisindolylmaleimide GF 109203X is a potent and selective inhibitor of protein kinase C. J. Biol. Chem. 266 (1991) 15771-15781
18. Yano H., Agatsuma T., Nakanishi S., Saitoh Y., Fukui Y., Nonomura Y., and Matsuda Y. Biochemical and pharmacological studies with KT7692 and LY294002 on the role of phosphatidylinositol 3-kinase in Fc epsilon RI-mediated signal transduction. Biochem. J. 312 Pt1 (1995) 145-150
19. Davies S.P., Reddy H., Caivano M., and Cohen P. Specificity and mechanism of action of some commonly used protein kinase inhibitors. Biochem. J. 351 (2000) 95-105
20. Alessi D.R., Andjelkovic M., Caudwell B., Cron P., Morrice N., Cohen P., and Hemmings B.A. Mechanism of activation of protein kinase B by insulin and IGF-1. EMBO J. 15 (1996) 6541-6551
21. Vlahos C.J., Matter W.F., Hui K.Y., and Brown R.F. A specific inhibitor of phosphatidylinositol 3-kinase, 2-(4-morpholinyl)-8-phenyl-4H-1-benzopyran-4-one (LY294002). J. Biol. Chem. 269 (1994) 5241-5248
22. Bennett B.L., Sasaki D.T., Murray B.W., O'Leary E.C., Sakata S.T., Xu W., Leisten J.C., Motiwala A., Pierce S., Satoh Y., Bhagwat S.S., Manning A.M., and Anderson D.W. SP600125, an anthrapyrazolone inhibitor of Jun N-terminal kinase. Proc. Natl. Acad. Sci. USA 98 (2001) 13681-13686
23. Favata M.F., Horiuchi K.Y., Manos E.J., Daulerio A.J., Stradley D.A., Feeser W.S., Van Dyk D.E., Pitts W.J., Earl R.A., Hobbs F., Copeland R.A., Magolda R.L., Scherle P.A., and Trzaskos J.M. Identification of a novel inhibitor of mitogen-activated protein kinase kinase. J. Biol. Chem. 273 (1998) 18623-18632
24. Sanchez M.G., Ruiz-Llorente L., Sanchez A.M., and Diaz-Laviada I. Activation of phosphoinositide 3-kinase/PKB pathway by CB(1) and CB(2) cannabinoid receptors expressed in prostate PC-3 cells. Involvement in Raf-1 stimulation and NGF induction. Cell Signal. 15 (2003) 851-859
25. Davis M.I., Ronesi J., and Lovinger D.M. A predominant role for inhibition of the adenylate cyclase/protein kinase A pathway in ERK activation by cannabinoid receptor 1 in N1E-115 neuroblastoma cells. J. Biol. Chem. 278 (2003) 48973-48980
26. Derkinderen P., Ledent C., Parmentier M., and Girault J.A. Cannabinoids activate p38 mitogen-activated protein kinases through CB1 receptors in hippocampus. J. Neurochem. 77 (2001) 957-960
27. Gustafsson K., Christensson B., Sander B., and Flygare J. Cannabinoid receptor-mediated apoptosis induced by R(+)-methanandamide and Win55, 212-2 is associated with ceramide accumulation and p38 activation in mantle cell lymphoma. Mol. Pharmacol. 70 (2006) 1612-1620
28. Paradisi A., Pasquariello N., Barcaroli D., and Maccarrone M. Anandamide regulates keratinocyte differentiation by inducing DNA methylation in a CB1 receptor-dependent manner. J. Biol. Chem. 283 (2008) 6005-6012
29. Govaerts S.J., Muccioli G.G., Hermans E., and Lambert D.M. Characterization of the pharmacology of imidazolidinedione derivatives at cannabinoid CB1 and CB2 receptors. Eur. J. Pharmacol. 495 (2004) 43-53
30. Burkey T.H., Quock R.M., Consroe P., Ehlert F.J., Hosohata Y., Roeske W.R., and Yamamura H.I. Relative efficacies of cannabinoid CB1 receptor agonists in the mouse brain. Eur. J. Pharmacol. 336 (1997) 295-298
31. Breivogel C.S., and Childers S.R. Cannabinoid agonist signal transduction in rat brain: comparison of cannabinoid agonists in receptor binding, G-protein activation, and adenylyl cyclase inhibition. J. Pharmacol. Exp. Ther. 295 (2000) 328-336
32. Felder C.C., Joyce K.E., Briley E.M., Mansouri J., Mackie K., Blond O., Lai Y., Ma A.L., and Mitchell R.L. Comparison of the pharmacology and signal transduction of the human cannabinoid CB1 and CB2 receptors. Mol. Pharmacol. 48 (1995) 443-450
33. Rhee M.H., Vogel Z., Barg J., Bayewitch M., Levy R., Hanus L., Breuer A., and Mechoulam R. Cannabinol derivatives: binding to cannabinoid receptors and inhibition of adenylylcyclase. J. Med. Chem. 40 (1997) 3228-3233
34. Glass M., and Northup J.K. Agonist selective regulation of G proteins by cannabinoid CB(1) and CB(2) receptors. Mol. Pharmacol. 56 (1999) 1362-1369
35. Georgieva T., Devanathan S., Stropova D., Park C.K., Salamon Z., Tollin G., Hruby V.J., Roeske W.R., Yamamura H.I., and Varga E. Unique agonist-bound cannabinoid CB1 receptor conformations indicate agonist specificity in signaling. Eur. J. Pharmacol. 581 (2008) 19-29
36. Guzman M., Sanchez C., and Galve-Roperh I. Cannabinoids and cell fate. Pharmacol. Ther. 95 (2002) 175-184
37. Guzman M. Effects on cell viability. Handbook Exp. Pharmacol. (2005) 627-642
38. Ozaita A., Puighermanal E., and Maldonado R. Regulation of PI3K/Akt/GSK-3 pathway by cannabinoids in the brain. J. Neurochem. 102 (2007) 1105-1114
39. Molina-Holgado F., Pinteaux E., Heenan L., Moore J.D., Rothwell N.J., and Gibson R.M. Neuroprotective effects of the synthetic cannabinoid HU-210 in primary cortical neurons are mediated by phosphatidylinositol 3-kinase/AKT signaling. Mol. Cell Neurosci. 28 (2005) 189-194
40. Greenhough A., Patsos H.A., Williams A.C., and Paraskeva C. The cannabinoid delta(9)-tetrahydrocannabinol inhibits RAS-MAPK and PI3K-AKT survival signalling and induces BAD-mediated apoptosis in colorectal cancer cells. Int. J. Cancer 121 (2007) 2172-2180
41. Ellert-Miklaszewska A., Kaminska B., and Konarska L. Cannabinoids down-regulate PI3K/Akt and Erk signalling pathways and activate proapoptotic function of Bad protein. Cell Signal. 17 (2005) 25-37
42. Sarker K.P., Biswas K.K., Yamakuchi M., Lee K.Y., Hahiguchi T., Kracht M., Kitajima I., and Maruyama I. ASK1-p38 MAPK/JNK signaling cascade mediates anandamide-induced PC12 cell death. J. Neurochem. 85 (2003) 50-61
43. Giuliano M., Calvaruso G., Pellerito O., Portanova P., Carlisi D., Vento R., and Tesoriere G. Anandamide-induced apoptosis in Chang liver cells involves ceramide and JNK/AP-1 pathway. Int. J. Mol. Med. 17 (2006) 811-819
44. Lee Y.M., Uhm K.O., Lee E.S., Kwon J., Park S.H., and Kim H.S. AM251 suppresses the viability of HepG2 cells through the AMPK (AMP-activated protein kinase)-JNK (c-Jun N-terminal kinase)-ATF3 (activating transcription factor 3) pathway. Biochem. Biophys. Res. Commun. 370 (2008) 641-645